| 000 | 01349 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250517140542.0 | ||
| 264 | 0 | _c20180529 | |
| 008 | 201805s 0 0 eng d | ||
| 022 | _a1179-1896 | ||
| 024 | 7 |
_a10.1007/s40258-017-0311-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRuggeri, M | |
| 245 | 0 | 0 |
_aEconomic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. _h[electronic resource] |
| 260 |
_bApplied health economics and health policy _cAug 2017 |
||
| 300 |
_a479-490 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aGuanine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aHealth Care Costs _xstatistics & numerical data |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aItaly _xepidemiology |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aTenofovir _xeconomics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBasile, M | |
| 700 | 1 | _aCoretti, S | |
| 700 | 1 | _aDrago, C | |
| 700 | 1 | _aCicchetti, A | |
| 773 | 0 |
_tApplied health economics and health policy _gvol. 15 _gno. 4 _gp. 479-490 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s40258-017-0311-4 _zAvailable from publisher's website |
| 999 |
_c26880620 _d26880620 |
||